Search Results - "GIOVANNONI, G"

Multiple sclerosis – a review by Dobson, R., Giovannoni, G.

“…Multiple sclerosis (MS) is the commonest non‐traumatic disabling disease to affect young adults. The incidence of MS is increasing worldwide, together with the…”
Get full text

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases by Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., Amor, S.

“…Based on the known and emerging biology of autoimmune diseases and COVID‐19, it was hypothesised that whilst B‐cell depletion should not necessarily expose…”
Get full text

Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude by Dobson, Ruth, Ramagopalan, Sreeram, Davis, Angharad, Giovannoni, Gavin

“…Background Oligoclonal bands (OCBs) unique to the cerebrospinal fluid are used in the diagnosis of multiple sclerosis (MS). The precise prevalence of OCBs in…”
Get full text

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary by Schmierer, K, Giovannoni, G

Get full text

The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude by Dobson, Ruth, Giovannoni, Gavin, Ramagopalan, Sreeram

“…Background Month of birth has previously been described as a risk factor for multiple sclerosis (MS). This has been hypothesised to be related to maternal…”
Get full text

Long COVID or post COVID-19 syndrome by Lechner-Scott, J., Levy, M., Hawkes, C., Yeh, A., Giovannoni, G.

Get full text

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence by Giovannoni, G, Southam, E, Waubant, E

“…Reviews of therapeutic drugs usually focus on the highly selected and closely monitored patient populations from randomized controlled trials. The objective of…”
Get full text

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis by Baker, D., Pryce, G., James, L. K., Schmierer, K., Giovannoni, G.

“…Clinical trials are probably the most informative experiments to help an understanding of multiple sclerosis (MS) biology. Recent successes with CD20‐depleting…”
Get full text

Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients by LEITE, M. I, COUTINHO, E, VILLA, A. M, CALLEGARO, D, SANTOS, E, DA SILVA, A. Martins, JARIUS, S, HOWARD, R, NAKASHIMA, I, GIOVANNONI, G, BUCKLEY, C, HILTON-JONES, D, LANA-PEIXOTO, M, VINCENT, A, PALACE, J, APOSTOLOS, S, WATERS, P, SATO, D, MELAMUD, L, MARTA, M, GRAHAM, A, SPILLANE, J

“…To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody (AQP4-Ab)-mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and…”
Get full text

The evidence for a role of B cells in multiple sclerosis by DISANTO, G, MORAHAN, J. M, BARNETT, M. H, GIOVANNONI, G, RAMAGOPALAN, S. V

“…Understanding the pathogenesis of complex immunologic disorders such as multiple sclerosis (MS) is challenging. Abnormalities in many different cell types are…”
Get full text

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function by KHARRI, B. O, MAN, S, DUDA, P. W, PANZARA, M. A, RANSOHOFF, R. M, FOX, R. J, GIOVANNONI, G, KOO, A. P, LEE, J.-C, TUCKY, B, LYNN, F, JURGENSEN, S, WOODWORTH, J, GOELZ, S

“…Accelerating the clearance of therapeutic monoclonal antibodies (mAbs) from the body may be useful to address uncommon but serious complications from…”
Get full text

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies by Havrdova, E., Giovannoni, G., Gold, R., Fox, R. J., Kappos, L., Phillips, J. Theodore, Okwuokenye, M., Marantz, J. L.

“…Background and purpose Significant effects on clinical/neuroradiological disease activity have been reported in patients with relapsing–remitting multiple…”
Get full text

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome by Kuhle, Jens, Gaiottino, Johanna, Leppert, David, Petzold, Axel, Bestwick, Jonathan P, Malaspina, Andrea, Lu, Ching-Hua, Dobson, Ruth, Disanto, Giulio, Norgren, Niklas, Nissim, Ahuva, Kappos, Ludwig, Hurlbert, John, Yong, V Wee, Giovannoni, Gavin, Casha, Steven

“…Background Neurofilaments (Nf) are major structural proteins that occur exclusively in neurons. In spinal cord injury (SCI), the severity of disease is…”
Get full text

Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force by Deisenhammer, F., Bartos, A., Egg, R., Gilhus, N. E., Giovannoni, G., Rauer, S., Sellebjerg, F.

“…A great variety of neurological diseases require investigation of cerebrospinal fluid (CSF) to prove the diagnosis or to rule out relevant differential…”
Get full text

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking by TEUNISSEN, C. E, PETZOLD, A, HINTZEN, R. Q, HUGHES, S. G, JOHNSON, M. H, KRASULOVA, E, KUHLE, J, MAGNONE, M. C, RAJDA, C, REJDAK, K, SCHMIDT, H. K, VAN PESCH, V, BENNETT, J. L, WAUBANT, E, WOLF, C, GIOVANNONI, G, HEMMER, B, TUMANI, H, DEISENHAMMER, F, BERVEN, F. S, BRUNDIN, L, COMABELLA, M, FRANCIOTTA, D, FREDERIKSEN, J. L, FLEMING, J. O, FURLAN, R

“…There is a long history of research into body fluid biomarkers in neurodegenerative and neuroinflammatory diseases. However, only a few biomarkers in CSF are…”
Get full text

Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment by Smets, I., Reyes, S., Baker, D., Giovannoni, G.

Get full text

Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis by Leist, T., Cook, S., Comi, G., Montalban, X., Giovannoni, G., Nolting, A., Damian, D., Syed, S., Galazka, A.

“…•We report the final clinical development program safety update for cladribine tablets.•A low level of serious treatment-emergent adverse events was…”
Get full text

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS by MILLER, D. H, SOON, D, KAPPOS, L, HUTCHINSON, M, HAVRDOVA, E, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A, RUDICK, R, LYNN, F, PANZARA, M. A, SANDROCK, A. W, FERNANDO, K. T, MACMANUS, D. G, BARKER, G. J, YOUSRY, T. A, FISHER, E, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H

“…In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients…”
Get full text

Apple Ripening Is Controlled by a NAC Transcription Factor by Migicovsky, Zoë, Yeats, Trevor H., Watts, Sophie, Song, Jun, Forney, Charles F., Burgher-MacLellan, Karen, Somers, Daryl J., Gong, Yihui, Zhang, Zhaoqi, Vrebalov, Julia, van Velzen, Robin, Giovannoni, James G., Rose, Jocelyn K. C., Myles, Sean

“…Softening is a hallmark of ripening in fleshy fruits, and has both desirable and undesirable implications for texture and postharvest stability. Accordingly,…”
Get full text

Multiple sclerosis: a practical overview for clinicians by Rejdak, Konrad, Jackson, Samuel, Giovannoni, Gavin

“…Multiple sclerosis (MS) is the commonest disabling neurological condition to afflict young adults and therefore has a high social burden. Over several decades,…”
Get full text